EPT0747
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- umap1_2d
- 3.973129343
- umap2_2d
- 5.588804353
- umap1_3d
- 1.592640394
- umap2_3d
- 1.060795161
- umap3_3d
- -1.385840838
- dataset
- EPN-Toronto
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- PANCREAS_BETA_CELLS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.130
- APICAL_SURFACE+0.110
- KRAS_SIGNALING_DN+0.110
- HEDGEHOG_SIGNALING+0.080
- MYC_TARGETS_V1+0.010
- XENOBIOTIC_METABOLISM-0.010
- WNT_BETA_CATENIN_SIGNALING-0.020
- KRAS_SIGNALING_UP-0.060
Top 10 suppressed
- ANGIOGENESIS-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- APOPTOSIS-0.420
- INTERFERON_GAMMA_RESPONSE-0.410
- CHOLESTEROL_HOMEOSTASIS-0.380
- HYPOXIA-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- UV_RESPONSE_DN-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG425 | — | — | 0.871 |
| 2 | 70d9a694-2379-4310-aa52-4fe388a58a8a | — | — | 0.862 |
| 3 | SRR650198 | — | — | 0.853 |
| 4 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.851 |
| 5 | SRR10899984 | — | — | 0.851 |
| 6 | s0112301 | — | — | 0.848 |
| 7 | SRR5088853 | — | — | 0.843 |
| 8 | R249 | — | — | 0.835 |
| 9 | SRR1485892 | GTEX | — | 0.834 |
| 10 | SRR1489054 | GTEX | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |